4//SEC Filing
PERCEPTIVE ADVISORS LLC 4
Accession 0001062993-21-001012
CIK 0001785345other
Filed
Feb 7, 7:00 PM ET
Accepted
Feb 8, 6:37 PM ET
Size
33.8 KB
Accession
0001062993-21-001012
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2021-02-08+1,770,600→ 1,770,600 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$16.00/sh+1,250,000$20,000,000→ 7,049,564 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total(indirect: See footnote)→ Common Stock (2,941,769 underlying) - Conversion
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total(indirect: See footnote)→ Common Stock (2,857,795 underlying) - Conversion
Common Stock
2021-02-08+2,857,795→ 5,799,564 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+2,941,769→ 2,941,769 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total(indirect: See footnote)→ Common Stock (2,857,795 underlying) - Conversion
Series B Preferred Stock
2021-02-08−1,770,600→ 0 total(indirect: See footnote)→ Common Stock (1,770,600 underlying) - Conversion
Common Stock
2021-02-08+2,857,795→ 5,799,564 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+2,941,769→ 2,941,769 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total(indirect: See footnote)→ Common Stock (2,941,769 underlying)
Holdings
- 3,090,924(indirect: See footnote)
Common Stock
PERCEPTIVE ADVISORS LLC
Director10% Owner
Transactions
- Conversion
Common Stock
2021-02-08+2,857,795→ 5,799,564 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total(indirect: See footnote)→ Common Stock (2,857,795 underlying) - Conversion
Series B Preferred Stock
2021-02-08−1,770,600→ 0 total(indirect: See footnote)→ Common Stock (1,770,600 underlying) - Conversion
Common Stock
2021-02-08+2,941,769→ 2,941,769 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total(indirect: See footnote)→ Common Stock (2,941,769 underlying) - Conversion
Common Stock
2021-02-08+2,857,795→ 5,799,564 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total(indirect: See footnote)→ Common Stock (2,941,769 underlying) - Conversion
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total(indirect: See footnote)→ Common Stock (2,857,795 underlying) - Conversion
Common Stock
2021-02-08+2,941,769→ 2,941,769 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+1,770,600→ 1,770,600 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$16.00/sh+1,250,000$20,000,000→ 7,049,564 total(indirect: See footnote)
Holdings
- 3,090,924(indirect: See footnote)
Common Stock
Xontogeny, LLC
Director
Transactions
- Conversion
Common Stock
2021-02-08+2,857,795→ 5,799,564 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+2,941,769→ 2,941,769 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total(indirect: See footnote)→ Common Stock (2,941,769 underlying) - Conversion
Series B Preferred Stock
2021-02-08−1,770,600→ 0 total(indirect: See footnote)→ Common Stock (1,770,600 underlying) - Purchase
Common Stock
2021-02-08$16.00/sh+1,250,000$20,000,000→ 7,049,564 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+2,941,769→ 2,941,769 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+1,770,600→ 1,770,600 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total(indirect: See footnote)→ Common Stock (2,941,769 underlying) - Conversion
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total(indirect: See footnote)→ Common Stock (2,857,795 underlying) - Conversion
Common Stock
2021-02-08+2,857,795→ 5,799,564 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total(indirect: See footnote)→ Common Stock (2,857,795 underlying)
Holdings
- 3,090,924(indirect: See footnote)
Common Stock
Transactions
- Conversion
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total(indirect: See footnote)→ Common Stock (2,941,769 underlying) - Conversion
Series B Preferred Stock
2021-02-08−1,770,600→ 0 total(indirect: See footnote)→ Common Stock (1,770,600 underlying) - Conversion
Common Stock
2021-02-08+2,857,795→ 5,799,564 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$16.00/sh+1,250,000$20,000,000→ 7,049,564 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total(indirect: See footnote)→ Common Stock (2,857,795 underlying) - Conversion
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total(indirect: See footnote)→ Common Stock (2,941,769 underlying) - Conversion
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total(indirect: See footnote)→ Common Stock (2,857,795 underlying) - Conversion
Common Stock
2021-02-08+2,857,795→ 5,799,564 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+2,941,769→ 2,941,769 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+2,941,769→ 2,941,769 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+1,770,600→ 1,770,600 total(indirect: See footnote)
Holdings
- 3,090,924(indirect: See footnote)
Common Stock
EDELMAN JOSEPH
Director
Transactions
- Conversion
Common Stock
2021-02-08+2,941,769→ 2,941,769 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+2,941,769→ 2,941,769 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+1,770,600→ 1,770,600 total(indirect: See footnote) - Conversion
Common Stock
2021-02-08+2,857,795→ 5,799,564 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-02-08−1,770,600→ 0 total(indirect: See footnote)→ Common Stock (1,770,600 underlying) - Conversion
Common Stock
2021-02-08+2,857,795→ 5,799,564 total(indirect: See footnote) - Purchase
Common Stock
2021-02-08$16.00/sh+1,250,000$20,000,000→ 7,049,564 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total(indirect: See footnote)→ Common Stock (2,941,769 underlying) - Conversion
Series A Preferred Stock
2021-02-08−2,941,769→ 0 total(indirect: See footnote)→ Common Stock (2,941,769 underlying) - Conversion
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total(indirect: See footnote)→ Common Stock (2,857,795 underlying) - Conversion
Series B Preferred Stock
2021-02-08−2,857,795→ 0 total(indirect: See footnote)→ Common Stock (2,857,795 underlying)
Holdings
- 3,090,924(indirect: See footnote)
Common Stock
Footnotes (6)
- [F1]Each share of the Issuer's Series A preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series A preferred stock had no expiration date.
- [F2]Each share of the Issuer's Series B preferred stock automatically converted into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.
- [F3]The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F4]The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F5]The securities are directly held by PX Venture (A), LLC. The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F6]The securities are directly held by Xontogeny, LLC ("Xontogeny"). C2 Ventures, LLC ("C2") is the manager of Perceptive XV Holdings, LLC ("Holdings"), the manager of Xontogeny. Joseph Edelman is the managing member of C2. Holdings, C2, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
Issuer
Landos Biopharma, Inc.
CIK 0001785345
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001224962
Filing Metadata
- Form type
- 4
- Filed
- Feb 7, 7:00 PM ET
- Accepted
- Feb 8, 6:37 PM ET
- Size
- 33.8 KB